Skip to Content
Reach blood sugar goals with long-acting insulin. Go >

Empagliflozin / linagliptin Disease Interactions

There are 4 disease interactions with empagliflozin / linagliptin:

Major

Dpp-4 Inhibitors (Includes Empagliflozin/linagliptin) ↔ Pancreatitis

Severe Potential Hazard, Low plausibility

Applies to: Pancreatitis

There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors. These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk. Patients should be observed for signs and symptoms of pancreatitis during treatment. If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.

Major

Sglt-2 Inhibitors (Includes Empagliflozin/linagliptin) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

The glucose lowering effects of SGLT-2 inhibitors is decreased in patients with worsening renal function. Additionally, SGLT-2 inhibitors increase serum creatinine and decrease eGFR. The elderly and patients with moderate renal impairment are at increased risk of further renal dysfunction. Renal function should be evaluated before treatment initiation and monitored regularly in these patients. The use of SGLT-2 inhibitors in patients with severe renal impairment, end stage renal dysfunction (ESRD), or undergoing dialysis is contraindicated. Based on its mechanism of action, SGLT-2 inhibitors are not expected to be effective in patients with this level of renal dysfunction.

Moderate

Sglt-2 Inhibitors (Includes Empagliflozin/linagliptin) ↔ Hyperlipidemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperlipidemia

There have been reports of dose-related increases in LDL cholesterol with the use of SGLT-2 inhibitors. Cholesterol levels should be monitored before and during treatment and appropriate therapy should be initiated if needed.

Moderate

Sglt-2 Inhibitors (Includes Empagliflozin/linagliptin) ↔ Hypotension

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction, Hypotension

SGLT-2 inhibitors cause intravascular volume contraction and symptomatic hypotension may occur after treatment initiation especially in the elderly, in patients with impaired renal function, low systolic blood pressure, or using diuretics . Volume status should be assessed and corrected before starting treatment and patients should be monitored during therapy.

empagliflozin / linagliptin drug Interactions

There are 789 drug interactions with empagliflozin / linagliptin

empagliflozin / linagliptin alcohol/food Interactions

There are 2 alcohol/food interactions with empagliflozin / linagliptin

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide